Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 8.5% – Still a Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s share price was up 8.5% on Wednesday . The company traded as high as $3.75 and last traded at $3.9810. 1,791,736 shares traded hands during trading, a decline of 90% from the average daily volume of 17,579,939 shares. The stock had previously closed at $3.67.

Wall Street Analyst Weigh In

Several research firms have commented on RXRX. Needham & Company LLC reissued a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 21st. Morgan Stanley upped their target price on Recursion Pharmaceuticals from $5.00 to $5.50 and gave the stock an “equal weight” rating in a research report on Thursday, May 14th. JPMorgan Chase & Co. lowered their target price on Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating for the company in a research note on Thursday, April 30th. Finally, Wall Street Zen downgraded Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $8.10.

Recursion Pharmaceuticals Stock Up 3.5%

The firm’s 50 day moving average price is $3.31 and its two-hundred day moving average price is $3.66. The firm has a market capitalization of $2.01 billion, a PE ratio of -3.17 and a beta of 1.00. The company has a quick ratio of 5.47, a current ratio of 5.47 and a debt-to-equity ratio of 0.01.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative net margin of 842.95% and a negative return on equity of 54.33%. The firm had revenue of $6.47 million for the quarter, compared to the consensus estimate of $15.78 million. During the same quarter in the previous year, the firm posted ($0.50) EPS. The firm’s quarterly revenue was down 56.8% on a year-over-year basis. As a group, research analysts forecast that Recursion Pharmaceuticals, Inc. will post -0.99 EPS for the current fiscal year.

Insider Activity

In related news, CEO Najat Khan sold 23,588 shares of the stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $3.58, for a total value of $84,445.04. Following the completion of the transaction, the chief executive officer owned 2,175,796 shares of the company’s stock, valued at approximately $7,789,349.68. This represents a 1.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $3.68, for a total value of $110,400.00. Following the sale, the director owned 6,169,863 shares of the company’s stock, valued at approximately $22,705,095.84. This trade represents a 0.48% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 121,937 shares of company stock valued at $421,574 over the last 90 days. Insiders own 6.65% of the company’s stock.

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of institutional investors have recently made changes to their positions in RXRX. Bank of America Corp DE grew its position in shares of Recursion Pharmaceuticals by 18.2% during the first quarter. Bank of America Corp DE now owns 2,496,831 shares of the company’s stock worth $7,665,000 after buying an additional 384,486 shares in the last quarter. Janus Henderson Group PLC increased its stake in shares of Recursion Pharmaceuticals by 59.4% in the first quarter. Janus Henderson Group PLC now owns 220,309 shares of the company’s stock worth $675,000 after buying an additional 82,100 shares during the last quarter. California State Teachers Retirement System raised its holdings in Recursion Pharmaceuticals by 64.0% in the first quarter. California State Teachers Retirement System now owns 574,637 shares of the company’s stock valued at $1,764,000 after acquiring an additional 224,332 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in Recursion Pharmaceuticals by 7.3% in the first quarter. The Manufacturers Life Insurance Company now owns 219,998 shares of the company’s stock valued at $675,000 after acquiring an additional 15,049 shares in the last quarter. Finally, Themes Management Co LLC bought a new position in Recursion Pharmaceuticals during the 1st quarter valued at $236,000. 89.06% of the stock is owned by institutional investors and hedge funds.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.